載入中
NASDAQHealthcareBiotechnology
最新資料
US$2.11
+US$0.03 · +1.44%
Canton Strategic Holdings Inc., which was formerly known as Tharimmune, Inc. until its name change in February 2026, focuses on two primary areas. The company is committed to promoting the institutional integration of blockchain technology and fostering the digitization of financial markets, primarily by leveraging Canton Coin and offering support to the Canton network. In addition to its blockchain initiatives, the company is also deeply involved in pharmaceutical research and development. Its pipeline includes GV104, a buccal film technology designed to address respiratory and/or nervous system depression in military personnel and chemical incident responders, which has already finished its Phase 1 trial. Another significant project is GV023, an oral version of infliximab, engineered to resolve the key inconvenience of the standard intravenous treatment by eliminating the need for recurring infusions. Established in 2017, Canton Strategic Holdings Inc. is headquartered in Red Bank, New Jersey.
前收盤價
US$2.11
+US$0.03 · +1.44%
盤中時間採用ET。市場資料可能有所延遲。
Canton Strategic Holdings Inc., which was formerly known as Tharimmune, Inc. until its name change in February 2026, focuses on two primary areas. The company is committed to promoting the institutional integration of blockchain technology and fostering the digitization of financial markets, primarily by leveraging Canton Coin and offering support to the Canton network. In addition to its blockchain initiatives, the company is also deeply involved in pharmaceutical research and development. Its pipeline includes GV104, a buccal film technology designed to address respiratory and/or nervous system depression in military personnel and chemical incident responders, which has already finished its Phase 1 trial. Another significant project is GV023, an oral version of infliximab, engineered to resolve the key inconvenience of the standard intravenous treatment by eliminating the need for recurring infusions. Established in 2017, Canton Strategic Holdings Inc. is headquartered in Red Bank, New Jersey.
日內區間
目前US$2.11
52週區間
目前US$2.11
盤中時間採用ET。市場資料可能有所延遲。
Canton Strategic Holdings Inc., which was formerly known as Tharimmune, Inc. until its name change in February 2026, focuses on two primary areas. The company is committed to promoting the institutional integration of blockchain technology and fostering the digitization of financial markets, primarily by leveraging Canton Coin and offering support to the Canton network. In addition to its blockchain initiatives, the company is also deeply involved in pharmaceutical research and development. Its pipeline includes GV104, a buccal film technology designed to address respiratory and/or nervous system depression in military personnel and chemical incident responders, which has already finished its Phase 1 trial. Another significant project is GV023, an oral version of infliximab, engineered to resolve the key inconvenience of the standard intravenous treatment by eliminating the need for recurring infusions. Established in 2017, Canton Strategic Holdings Inc. is headquartered in Red Bank, New Jersey.
日內區間
目前US$2.11
52週區間
目前US$2.11
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 307.4萬 USD | 639.21萬 USD | 355.96萬 USD | 227.84萬 USD | 184.28萬 USD |
| 銷售、一般及管理費用 | 1703.21萬 USD | 604.17萬 USD | 589.56萬 USD | 460.35萬 USD | 136.52萬 USD |
| 營業費用 | 2010.61萬 USD | 1243.38萬 USD | 945.52萬 USD | 688.19萬 USD | 320.8萬 USD |
| 利息收入 | 4.14萬 USD | 24.99萬 USD | 15.26萬 USD | — | — |
| 利息支出 | 2.83萬 USD | 1.37萬 USD | 1.65萬 USD | 159.12萬 USD | 83.13萬 USD |
| 折舊和攤銷 | 2201.04萬 USD | — | 945.52萬 USD | 156.9萬 USD | — |
| 營業利益 | −2010.61萬 USD | −1243.38萬 USD | −945.52萬 USD | −688.19萬 USD | −320.8萬 USD |
| 淨利 | −3591.63萬 USD | −1219.76萬 USD | −931.91萬 USD | −847.32萬 USD | −220.66萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2024年5月28日 | 1:15 | — | — |
股票分割 | 2023年11月21日 | 1:25 | — | — |
已生效 2024年5月28日
1:15
已生效 2023年11月21日
1:25
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI499.03萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM318.73萬0.00%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF181.87萬0.00%954億 USD0.05%US$235+0.80%
ARK Blockchain & Fintech Innovation ETFARKF88.48萬0.10%7.01億 USD0.75%US$47.59+2.52%
Vanguard Russell 2000 ETFVTWO57.77萬0.00%180億 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC42.76萬0.03%13.17億 USD0.60%US$183+0.11%
Vanguard Russell 2000 Value ETFVTWV9.37萬0.01%14億 USD0.06%US$185.81-0.13%
iShares Blockchain and Tech ETFIBLC7.76萬0.10%7852.05萬 USD0.47%US$42.985-0.03%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFARK Blockchain & Fintech Innovation ETFARKFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Value ETFVTWViShares Blockchain and Tech ETFIBLCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
